BioSpace News Archive

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced new preclinical data showcasing simultaneous and coordinated pre-transcriptional control of multiple genes co-located in an insulated genomic domain (IGD) by a single epigenomic controller (EC) at the 11th International mRNA Health Conference taking place in Berlin, Germany, October 31 – November 2, 2023.

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets.

Avalo Therapeutics, Inc., announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801, AVTX-802 and AVTX-803 to AUG Therapeutics, LLC.

Galera Therapeutics, Inc. announced that it has received official meeting minutes from the Type A meeting with the United States Food and Drug Administration held September 28, 2023 in which the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM.

Basilea Pharmaceutica Ltd announced that it has entered into an exclusive evaluation license and option agreement for tonabacase, with iNtRON Biotechnology, Inc., a company based in the Republic of Korea.

Sosei Group Corporation will receive a US$3.75 million milestone payment under the 2019 multi-target Research Collaboration and License Agreement with Genentech, a member of the Roche Group.

Sosei Group Corporation announces that Idorsia Pharmaceuticals Japan Ltd., a Sosei Group company, has submitted a New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the approval of daridorexant, a dual orexin receptor antagonist which has been co-developed with Mochida Pharmaceutical Co., Ltd., for the treatment of adult patients with insomnia.

Sigrid Therapeutics successfully secured $4 million in an oversubscribed funding round. The investment, made by both existing and new investors, underlines the strong investor confidence in Sigrid’s innovative SiPore® technology.